Mizuho Issues Positive Forecast for Immix Biopharma (NASDAQ:IMMX) Stock Price

Immix Biopharma (NASDAQ:IMMX) had its target price raised by equities researchers at Mizuho from $14.00 to $15.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s target price indicates a potential upside of 80.27% from the company’s current price.

Other research analysts have also issued research reports about the company. Morgan Stanley assumed coverage on Immix Biopharma in a report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. HC Wainwright upped their price objective on shares of Immix Biopharma from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Citizens Jmp restated a “market outperform” rating and issued a $23.00 target price on shares of Immix Biopharma in a research note on Friday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Immix Biopharma presently has an average rating of “Moderate Buy” and an average target price of $18.25.

Immix Biopharma Trading Up 2.1%

Shares of IMMX traded up $0.17 during mid-day trading on Monday, hitting $8.32. 116,583 shares of the company’s stock were exchanged, compared to its average volume of 874,850. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $11.61. The business’s 50 day moving average is $7.77 and its two-hundred day moving average is $5.28. The firm has a market capitalization of $440.76 million, a P/E ratio of -9.38 and a beta of 0.25.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.12). On average, equities research analysts forecast that Immix Biopharma will post -0.87 earnings per share for the current year.

Institutional Investors Weigh In On Immix Biopharma

Institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new position in shares of Immix Biopharma in the 4th quarter valued at about $20,471,000. Eventide Asset Management LLC acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at approximately $13,331,000. Marshall Wace LLP grew its holdings in Immix Biopharma by 3,495.4% during the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after buying an additional 1,923,708 shares during the last quarter. Millennium Management LLC acquired a new position in Immix Biopharma in the 4th quarter valued at about $8,681,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Immix Biopharma during the fourth quarter valued at approximately $7,845,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.